newsfilter
← Latest News
GlobeNewswire·

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01